1 Department of Medicine, University of Rochester School of Medicine, Rochester, New York
2 Department of Pharmacology and Physiology, University of Rochester School of Medicine, Rochester, New York
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Use of protease inhibitors has remarkably improved long-term survival after HIV infection (1,2). However, up to 60% of HIV-infected patients treated with these agents develop either impaired glucose tolerance (IGT) or type 2 diabetes (36), and it now appears to be well established that regimens including protease inhibitors are associated with insulin resistance (2,5,7,8). Noor et al. (9,10) have shown that acute and 4-week protease inhibitor exposure of normal volunteers reduces glucose disposal during euglycemic-hyperinsulinemic clamp experiments. Moreover, in vitro studies have demonstrated that protease inhibitors reduce insulin-stimulated glucose uptake in adipocytes and skeletal muscle (11,12).
Knowledge of the mechanisms responsible for deterioration in glucose tolerance during protease inhibitorcontaining regimens is still incomplete. It is unclear whether protease inhibitors adversely affect pancreatic ß-cell function (4,8) and what effect they have on glucose production and free fatty acid (FFA) turnover. Protease inhibitors are aspartate endopeptidase inhibitors (1315). Because an aspartate endopeptidase is involved in converting proinsulin to insulin, the observation that plasma proinsulin levels are increased in protease inhibitortreated patients (5) suggests that these drugs may directly impair pancreatic ß-cell function. Increased plasma FFA levels have been found in protease inhibitortreated patients (16), and it is not known whether this is due to increased release or decreased utilization.
This study was undertaken to prospectively assess the effect of protease inhibitorbased treatment regimens on pancreatic ß-cell function and to determine the sites of insulin resistance. We studied 13 HIV-infected subjects with normal glucose tolerance before and after 12 weeks of protease inhibitorbased treatment and 14 healthy normal volunteers using hyperglycemic clamp experiments in combination with isotopic determination of glucose and FFA turnover. Eight of the patients had been on a chronic regimen containing nucleoside reverse transcriptase inhibitors (NRTIs) to which a protease inhibitor was added, and five patients were drug naïve and were started on a combination of an NRTI and a protease inhibitor.
![]() |
RESEARCH DESIGN AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
On each study occasion subjects were admitted to the clinical research center at 5:00 P.M. the day before the experiment. Between 6:00 P.M. and 7:00 P.M. a standard dinner (10 kcal/kg: 50% carbohydrate, 35% fat, and 15% protein) was given. At 5:00 A.M. the following morning, primed-continuous infusions of [6,6-2H2]glucose (24 µmol/kg, 0.24 µmol · kg-1 · min-1) and [9,10-3H]palmitate (0.8 µCi/min) were started via a forearm vein. At 6:00 A.M. a retrograde venous catheter was inserted into a dorsal hand vein and maintained in a thermoregulated box at 65°C to obtain arterialized blood samplings (18). After allowing at least 2 h to achieve isotopic steady state, baseline samples for substrate enrichments, specific activities, plasma glucose, FFAs, glycerol, insulin, glucagon, C-peptide, and proinsulin concentrations were collected at -30, -15, and 0 min. Just before beginning the clamp, subjects took their medications. Subsequently, a primed (150 mg/kg body wt) 20% glucose infusion was given and plasma glucose levels were clamped at 10 mmol/l (180 mg/dl) for 3 h (19).
Plasma insulin, proinsulin, and C-peptide concentrations were measured at 2.5, 5.0, 7.5, 10, 15, 30, 60, 90, 120, 140, 160, and 180 min. Samples for plasma glucose, FFA, glucagon, glycerol concentrations, enrichments, and specific activities (SAs) were collected during the last hour of the clamp at 20-min intervals (120, 140, 160, and 180 min). Plasma glucose was measured at 5-min intervals throughout for adjustments of glucose infusion rates using a glucose analyzer (YSI Glucose Analyzer; Yellow Springs Instruments). Plasma insulin (Linco Research), proinsulin (Linco Research), C-peptide (Diagnostic Product), and glucagon (Linco Research) were measured by standard radioimmunoassays. Plasma FFA levels were measured by an enzymatic calorimetric method (NEFAC; Wako Pure Chemical). Plasma glycerol concentrations were determined by standard microfluorometric assays (20). HbA1c was determined by high-performance liquid chromatography (HPLC).
Plasma [6,6-2H2]glucose enrichments were measured by gas chromatography mass spectroscopy (21), and plasma palmitate concentrations and SAs were determined by a previously described HPLC technique (22) with coefficients of variation of 3.8 and 2.3%, respectively. Total body fat and fat-free mass was determined by bioimpedance measurements (23).
Calculations.
First-phase insulin release was calculated as the sum of the increments of C-peptide above baseline at 2.5, 5.0, 7.5, and 10 min. Second-phase insulin release was calculated as the average C-peptide concentration during the last hour of the clamp (24). Insulin sensitivity index (25) was calculated by dividing the average glucose infusion rate during the last hour of the clamp (µmol · kg-1 · min-1) by the product of the average plasma insulin (pmol/l) and glucose (mmol/l) concentration during the same time interval (25).
ß-Cell function and insulin sensitivity were also assessed by using HOMA as previously described (26). Insulin sensitivity (ISHOMA) was calculated as ISHOMA = 1/(135 x insulin x glucose), i.e., the inverse of insulin resistance. ß-Cell function (SECRhoma) was calculated as SECRhoma = C-peptide x 3.33/(GLUC - 3.5), where C-peptide (pmol/l) represents the average fasting plasma C-peptide concentration and GLUC (mmol/l) the average fasting plasma glucose concentration (27). C-peptide was used in place of the originally proposed plasma insulin because of changes in insulin metabolism induced by protease inhibitor treatment as described below. To evaluate the appropriateness of changes in ß-cell function in relation to changes in insulin sensitivity, the disposition index (28) was calculated as the product of ß-cell function and insulin sensitivity determined during the clamp experiments.
During the basal state before the clamp, rates of appearance and disappearance (turnover) of FFA were calculated using the steady-state equation for the infusion of radioactive isotopes Ra(Rd) = F/SA (29), where Ra represents the rate of appearance, Rd the rate of disappearance, F the infusion rate of tracer (dpm · min-1 · kg-1), and SA the specific activity (dpm · µmol-1). For glucose turnover, isotope enrichments (%) were substituted for SAs and corrected for the proportion of infused [6,6-2H2]glucose by subtracting its infusion rate from Ra(Rd). Glucose enrichments and palmitate SAs were not significantly different from one another, indicating that isotopic steady state had been achieved. Because there is evidence that NRTIs may be associated with insulin resistance (30), subjects were divided into two groups. Group 1 (NRTI pretreated, n = 8) had been on an NRTI and had a protease inhibitor added; group 2 (NRTI naïve, n = 5) had been drug naïve and were started on an NRTI and a protease inhibitor. The data of these groups were compared in an attempt to factor out the effects of protease inhibitors. Furthermore, baseline data of NRTI ± pretreated volunteers was compared with those of 14 healthy subjects to determine whether NRTI pretreatment had effects on insulin sensitivity and ß-cell function. Unless specified otherwise, data are given as the mean ± SE and were initially evaluated by ANOVA for repeated measurements followed by Wilcoxons matched pairs test comparing baseline data with results after 12 weeks of treatment. Mann-Whitney tests were used to compare changes between the groups during the treatment period as well as baseline data. Correlations between variables were performed using Spearmans regression analysis.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
Fasting plasma glycerol increased (P = 0.02), whereas plasma FFAs, triglycerides, and total and HDL cholesterol remained unchanged (all P > 0.13). However, plasma LDL cholesterol increased slightly but significantly (P = 0.03).
ß-Cell function and insulin sensitivity
HOMA.
Baseline values and responses to treatment were not significantly different in NRTI-pretreated and NRTI-naïve subjects. At baseline, both groups had comparable insulin sensitivity and ß-cell function with those of normal volunteers. After 12 weeks of treatment, both insulin sensitivity and pancreatic ß-cell function decreased significantly (P = 0.002 and 0.003, respectively) (Tables 5 and 6 and Fig. 1).
|
|
|
Systemic glucose and FFA turnovers and clearances.
Baseline values and responses to treatment did not differ among the patient groups. Fasting plasma glucose turnover, which was normal at baseline, decreased significantly after treatment (P = 0.002). The product of basal plasma insulin and glucose turnover, an index of the appropriateness of endogenous glucose production for the prevailing insulinemia, remained unchanged in both groups, suggesting appropriate suppression of endogenous glucose production. Glucose clearance, which was normal at baseline, decreased significantly (P < 0.001), indicating peripheral insulin resistance. Although plasma FFA concentrations did not change as indicated above, both fasting plasma FFA turnover and clearance increased significantly after treatment (both P < 0.001) (Table 7).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
After 12 weeks of treatment, we found a deterioration in glucose tolerance in all subjects, as indicated by increased fasting plasma glucose levels. Insulin sensitivity decreased by 4050% as determined by HOMA and the hyperglycemic clamp technique. Overall pancreatic ß-cell function, as assessed by HOMA, and first-phase insulin release, assessed during hyperglycemic clamp experiments, decreased significantly. Second-phase insulin release during the hyperglycemic clamp experiments was not reduced in an absolute sense but with use of the disposition index, an assessment of the appropriateness of ß-cell function for a given degree of insulin resistance, it was found to be reduced significantly. Thus, it appears that first-phase insulin release was more severely affected than second- phase insulin release. Our results thus confirm that protease inhibitor treatment of HIV-infected individuals is associated with insulin resistance (2,7,33); furthermore, our results demonstrate that this insulin resistance is not accompanied by an appropriate compensatory increase in insulin secretion. Indeed, there was a strong correlation between deterioration of the disposition index and the increase in fasting plasma glucose concentrations (r = 0.645).
Various protease inhibitors (indinavir, nelfinavir, lopinovir, saquinavir, and ritonavir) have been reported to cause insulin resistance either in vivo or in vitro (1,5,12,34,35). It has been suggested that inducement of insulin resistance by protease inhibitors may be a class effect (33), although these agents may differ in the extent to which they affect insulin sensitivity (7). However, our study was not designed or powered to detect differences in magnitude among these agents, but rather to assess the mechanisms responsible for the associated deterioration in glucose tolerance. Since most of our subjects received nelfinavir, the conclusion of a class effect must be drawn with caution.
Regarding the mechanisms/sites of insulin resistance induced by protease inhibitor treatment, we found a reduction in glucose disposal, whereas glucose production appeared to be appropriately reduced for the prevailing plasma insulin concentration. Under euglycemic-hyperinsulinemic clamp conditions, most glucose disposal occurs in skeletal muscle (25). Indinavir has been shown to inhibit muscle glucose transport (36). Our results thus provide additional evidence that these agents reduce skeletal muscle insulin sensitivity.
Furthermore, our findings suggest that there was also insulin resistance in adipose tissue. Although plasma FFA concentrations did not change, plasma glycerol concentrations and plasma FFA turnover increased. Because this occurred in the face of increased plasma insulin levels, these observations provide evidence for impaired suppression of lipolysis by insulin. The latter is consistent with recent reports that nelfinavir, saquinavir, and ritonavir increase lipolysis (11,35,37).
We found no alteration of plasma lipids except for an increase in LDL cholesterol. Previous studies have found no effect of indinavir and ritonavir on LDL cholesterol in normal volunteers, whereas in HIV-infected individuals protease inhibitors appear to consistently increase LDL cholesterol and have variable effects on triglycerides (9,38,39).
Recently, the HIV-lipodystrophy syndrome (HLS), a condition characterized by changes in body fat redistribution, peripheral and facial fat loss, dyslipidemia, and insulin resistance has been associated with protease inhibitor and NRTI therapy (40). It has been suggested that the changes in lipid metabolism associated with the HLS may be at least partially responsible for a deterioration in glucose tolerance (41). We did not find any significant changes in body fat content and lean body mass or any clinical signs of fat redistribution in our patients either before or after treatment. However, we did not assess changes in body fat distribution with magnetic resonance imaging or computer tomography (CT). Thus, we cannot exclude that subtle changes in body composition might have occurred. However, changes in glucose tolerance have been reported to take place with protease inhibitors without detectable changes in body composition determined by CT (9). However, we did find an increase in FFA turnover and clearance after treatment. Recently, Sekhar et al. (42) provided strong evidence that the HLS is associated with increased FFA turnover and suggested that this reflected ongoing fat redistribution. Thus, the increased FFA turnover that we found in the absence of obvious lipodystrophy may be an early indicator for changes in lipid metabolism, which might eventually lead to the development of lipodystrophy. On the other hand, the increased FFA turnover may simply reflect insulin resistance accompanying the treatment unrelated to the HLS. Nevertheless, the insulin resistance in type 2 diabetes is characterized by normal FFA turnover and reduced FFA clearance (43,44).
The molecular mechanism for the deterioration in pancreatic ß-cell function found in the present study and in a preliminary report in nelfinavir-treated rats (45) remains to be elucidated. It had been initially speculated that protease inhibitors may impair ß-cell function by inhibiting one of the endopeptidases involved in the cleavage of proinsulin to insulin (4), because increased plasma insulintoproinsulin ratios were found in protease inhibitortreated patients (5). In the present studies we found the opposite. Moreover, subsequent studies (46) in which islet cells were incubated with protease inhibitors did not show any adverse effect on the conversion of proinsulin to insulin. Thus, endopeptidase inhibition does not seem to be involved.
There is evidence, however, that insulin itself may be important for maintaining normal ß-cell function based on the finding of reduced insulin release in mice with knockout of the insulin receptor and insulin receptor substrate-2 (47). Conceivably, therefore, the same mechanism by which protease inhibitorcontaining regimens cause insulin resistance in the peripheral tissues might be operative in the pancreatic ß-cell.
It is noteworthy that in the present study the ratio of plasma proinsulin to plasma insulin and the ratio of plasma C-peptide to plasma insulin both decreased significantly with treatment, whereas the ratio of plasma proinsulin to plasma C-peptide was unaltered. Because insulin and C-peptide are secreted from the ß-cell in equimolar amounts, changes in the ratio of plasma C-peptide to plasma insulin would reflect a change in the clearance of insulin or C-peptide. The above findings are therefore consistent with the conclusion that insulin clearance had been reduced. If C-peptide clearance been altered, one would expect to find a change in the plasma proinsulintoplasma C-peptide ratio. The practical significance of this finding is that changes in plasma insulin concentrations cannot be used as an index of ß-cell function during treatment with protease inhibitorcontaining regimens.
In conclusion, the present study indicates that protease inhibitorcontaining regimens impair glucose tolerance in HIV-infected patients by two mechanisms: 1) inducement of peripheral insulin resistance in skeletal muscle and adipose tissue and 2) reduction in pancreatic ß-cell function. There are several clinical implications of this study. First, use of these regimens may cause deterioration of glycemic control in patients with preexisting diabetes. Second, because these regimens appear to induce insulin resistance predominantly in skeletal muscle and adipose tissue, antidiabetic agents that exert their major action on peripheral tissues rather than on the liver (e.g., thiazolidinediones) would appear advantageous (48). Third, because first-phase insulin release appears to be more severely impaired than second-phase insulin release, secretagogues such as the meglitinides, which primarily improve first-phase insulin release (49), may be preferable to sulfonylureas, which apparently only affect second-phase insulin release (49).
![]() |
ACKNOWLEDGMENTS |
---|
We thank Mary Little for her excellent editorial assistance and the nursing and laboratory staff of the General Clinical Research Center for their superb help.
![]() |
FOOTNOTES |
---|
Received for publication 10 May 2002 and accepted in revised form 2 January 2003.
R.C.R. has received financial support from GlaxoSmithKline, Agouron Pharmaceuticals, MedImmue, Triangle Pharmaceuticals, and Gilead Sciences.
CT, computer tomography; FFA, free fatty acid; HLS, HIV-lipodystrophy syndrome; HOMA, homeostasis model assessment; HPLC, high-performance liquid chromatography; IGT, impaired glucose tolerance; ISHOMA, insulin sensitivity measured by HOMA; NRTI, nucleoside reverse transcriptase inhibitor; SA, specific activity; SECRhoma, ß-cell function measured by HOMA.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|